Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
Anika Therapeutics (NASDAQ:ANIK – Free Report) had its target price reduced by Barrington Research from $25.00 to $20.00 in a research note released on Thursday,Benzinga reports. They currently have ...
A Brief Overview ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback